Peptonic Medical AB (publ) closes a 6 MSEK rights issue to a group of new investors
Stockholm, August 3rd, 2016. Peptonic Medical AB (publ) (“Peptonic Medical” or the “Company”) - a company developing pharmaceutical products based on oxytocin - today announced that it has completed a rights issue of 6 MSEK (before transaction costs equivalent to 10% of the total rights issue amount ), to a selected group of new investors, in accordance with the mandate given to the Board of Directors at the Annual General Meeting on May 19th 2016. A total of 1 428 572 shares were issued at a subscription price of SEK 4.20 per share. This share price is equivalent to a 20.06% discount